123 related articles for article (PubMed ID: 38820045)
1. Erratum to: Clinical significance of Notch receptors in triple negative breast cancer.
Shah H; Mistry M; Patel N; Vora H
Breast Dis; 2024; 43(1):159. PubMed ID: 38820045
[No Abstract] [Full Text] [Related]
2. Clinical significance of Notch receptors in triple negative breast cancer.
Shah H; Mistry M; Patel N; Vora H
Breast Dis; 2023; 42(1):85-100. PubMed ID: 36970890
[TBL] [Abstract][Full Text] [Related]
3. A molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway.
Pardo I; Fagundes PB; Oliveira RS; Campregher PV
Einstein (Sao Paulo); 2024; 22():eRW0552. PubMed ID: 38324848
[TBL] [Abstract][Full Text] [Related]
4. The functional role of Notch signaling in triple-negative breast cancer.
Speiser JJ; Erşahin C; Osipo C
Vitam Horm; 2013; 93():277-306. PubMed ID: 23810012
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
6. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
[TBL] [Abstract][Full Text] [Related]
7. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
8. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
9. Bulbine frutescens phytochemical inhibits notch signaling pathway and induces apoptosis in triple negative and luminal breast cancer cells.
Kushwaha PP; Vardhan PS; Kapewangolo P; Shuaib M; Prajapati SK; Singh AK; Kumar S
Life Sci; 2019 Oct; 234():116783. PubMed ID: 31442552
[TBL] [Abstract][Full Text] [Related]
10. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
Li B; Huang L; Ruan J
Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
[TBL] [Abstract][Full Text] [Related]
11. Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype.
Giuli MV; Giuliani E; Screpanti I; Bellavia D; Checquolo S
J Oncol; 2019; 2019():8707053. PubMed ID: 31379945
[TBL] [Abstract][Full Text] [Related]
12. Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Ortiz-Martínez F; Gutiérrez-Aviñó FJ; Sanmartín E; Pomares-Navarro E; Villalba-Riquelme C; García-Martínez A; Lerma E; Peiró G
Exp Mol Pathol; 2016 Jun; 100(3):460-8. PubMed ID: 27118257
[TBL] [Abstract][Full Text] [Related]
13. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
Nowacka-Zawisza M; Krajewska WM
Postepy Hig Med Dosw (Online); 2013 Nov; 67():1090-7. PubMed ID: 24379250
[TBL] [Abstract][Full Text] [Related]
14. Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer.
Orzechowska M; Jędroszka D; Bednarek AK
Oncotarget; 2017 Jan; 8(4):6013-6032. PubMed ID: 27888801
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
Valcourt DM; Dang MN; Scully MA; Day ES
ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
[TBL] [Abstract][Full Text] [Related]
16. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
17. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway.
Pan H; Zhou W; He W; Liu X; Ding Q; Ling L; Zha X; Wang S
Int J Mol Med; 2012 Aug; 30(2):337-43. PubMed ID: 22580499
[TBL] [Abstract][Full Text] [Related]
18. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer.
Speiser J; Foreman K; Drinka E; Godellas C; Perez C; Salhadar A; Erşahin Ç; Rajan P
Int J Surg Pathol; 2012 Apr; 20(2):139-45. PubMed ID: 22084425
[TBL] [Abstract][Full Text] [Related]
19. The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells.
Pamarthy S; Jaiswal MK; Kulshreshtha A; Katara GK; Gilman-Sachs A; Beaman KD
Oncotarget; 2015 Oct; 6(33):34206-20. PubMed ID: 26418877
[TBL] [Abstract][Full Text] [Related]
20. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
